Clinical trial
Effects of SGLT-2 Inhibitor Dapagliflozin on Hormonal Glucose Regulation and Ketogenesis in Patients With Type 1 Diabetes - a Randomised, Placebo-controlled, Open-label, Cross-over Intervention Study
NCT04035031 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of SGLT-2 Inhibitor Dapagliflozin on Hormonal Glucose Regulation and Ketogenesis in Patients With Type 1 Diabetes - a Randomised, Placebo-controlled, Open-label, Cross-over Intervention Study
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 9, 2020
- Completion date
- November 12, 2020
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.